Ignite Creation Date:
2025-12-24 @ 3:30 PM
Ignite Modification Date:
2026-01-04 @ 2:53 AM
Study NCT ID:
NCT02684292
Status:
COMPLETED
Last Update Posted:
2025-12-23
First Post:
2016-02-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-05-23
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-10
Completion Date Type:
ACTUAL
First Submit Date:
2016-02-12
First Submit QC Date:
None
Study First Post Date:
2016-02-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-19
Last Update Post Date:
2025-12-23
Last Update Post Date Type:
ESTIMATED